Participated · Series A · Apr 2026

Keebler Health builds an LLM-native platform that processes unstructured clinical documentation at scale to surface missed hierarchical condition category (HCC) coding opportunities and deliver actionable clinician insights at the point of care. The platform targets both retrospective and concurrent workflows to enable appropriate revenue capture without disrupting existing clinical operations. Keebler positions risk adjustment as its initial focus while planning to expand into broader population health use cases, Next Best Diagnostic Action, and compliance/audit workflows such as RADV audit readiness. The company was founded in 2023 by Isaac Park, Andrew Stickney, and Kevin Hill, PhD, with Terrell Bacchus, MD as founding CMO, and is headquartered in Durham, North Carolina. Financially, Keebler has raised $23 million to date, including the $16 million Series A announced in this round.

Participated · Series A · Jan 2026

Think Bioscience leverages a proprietary synthetic biology platform to identify previously hidden binding pockets on proteins that have long been considered undruggable. By coupling high-throughput functional surveys with protein biophysics, enzymology, and computational chemistry, the company designs first-in-class small molecules across a wide array of target classes, including transcription factors, phosphatases, kinases, proteases, and GTPases. Its lead program addresses mutant proteins that drive Noonan syndrome, a genetic disorder affecting roughly 1 in 2,500 births and currently lacking disease-modifying therapies. Beyond this flagship effort, the company is advancing a “robust internal pipeline” of additional programs built on the same discovery engine. The new Series A financing brings in significant capital to expand these programs and further validate the platform. Think Bioscience remains privately held and has not disclosed revenue or patient enrollment metrics to date.

Participated · Series A · May 2025

Vivodyne operates a robotics-plus-AI platform that grows thousands of fully functional human tissues and generates large-scale human multi-omic datasets to improve preclinical prediction. Its system produces imaging, single-cell transcriptomics, and proteomics from more than 10,000 independent human-tissue experiments per robotic run and can generate data from tens of thousands of complex tissues. The platform grows tissues a thousand times larger than typical organoids, supports over 20 distinct human tissue types, and models diseases including cancer, fibrosis, autoimmunity, and infections. Vivodyne’s AI actively designs and optimizes candidate therapies across modalities such as small molecules, biologics, mRNA lipid nanoparticles, and cell therapies. The company reports that most of the world’s leading pharmaceutical companies already use its technology and is positioning to replace animal models across the preclinical pipeline. To scale capacity and meet surging pharma demand, Vivodyne is opening a 23,000 sq ft fully robotic laboratory in South San Francisco. Vivodyne builds an automated platform that cultivates, doses, samples, images, and analyzes lab-grown human organ tissues to produce large, human-predictive datasets powering a clinically predictive AI stack. The company has bioengineered over 20 types of human organ tissues that mimic native human physiology and can cultivate and analyze more than 10,000 individual human tissues at a time using robotic automation. Its AI pipelines identify novel therapeutic targets and predict patient responses to drugs, and Vivodyne has used the platform across modalities including small molecules, biologics, mRNA lipid nanoparticles, and cell therapies. The company says its datasets are larger and more human-predictive than conventional preclinical models, addressing a key bottleneck in drug development. Vivodyne reports collaborations with the majority of the top 10 large pharma companies and intends to advance its discovery pipeline and multimodal AI models with new funding. The founders, University of Pennsylvania bioengineers Andrei Georgescu and Dan Huh, lead the company’s technology and research efforts.

Participated · Series A · May 2025

Persist AI offers an AI-driven robotics platform and Cloud Lab that lets pharmaceutical scientists remotely predict, build, and test formulations using miniaturized, automated laboratory facilities. Its AI models generate formulation recipes and the robotic systems execute high-throughput experiments, dramatically reducing material use and timelines. In a recent engagement, Persist identified an optimal long-acting injectable in two months by building and testing 700 formulations, versus an industry standard of roughly 10–15 formulations per month. The Cloud Lab supports modalities including peptides, small molecules, antibodies, and antisense oligonucleotides, and serves multiple top-10 pharmaceutical clients as well as smaller biotechs. Persist plans to expand its robotic lab, broaden the range of formulations its models can predict and test, and build comprehensive datasets to improve its AI. The company is Y Combinator–backed (graduated 2023) and recently closed a $12 million Series A to fund these efforts. Persist AI is an AI-driven drug formulation company based in Woodland, CA. The company has developed robotics that enable automated development of long-acting injectable formulations. Coupled with AI models, their technology rapidly predicts which formulations will release drugs in the body for an extended period and reduce the number of injections patients need. Led by CEO Karthik Raman, Persist AI completed YCombinator and subsequently raised $4M in seed financing. The round was led by 2048 Ventures with participation from Innospark Ventures, Fellows Fund, YCombinator, Pioneer Fund and others. Persist AI intends to use the funds to expand operations and further its development efforts.

Participated · Series B · Feb 2025

Tidal Vision develops scalable chitosan-based biomolecular solutions for critical industries including water treatment, agriculture, and material science. Headquartered in Bellingham, Wash., the company positions chitosan chemistries as higher-performing, more economical, and easier-to-adopt alternatives. It holds an expanding intellectual property portfolio around chitosan extraction, modification, characterization, and commercial applications. The company is investing in expanded commercial-scale and R&D facilities to increase production capacity and global accessibility. Proceeds from its recent financing will accelerate R&D in chitosan and adjacent technologies and fund new infrastructure. Tidal Vision frames its mission as creating positive, systemic environmental impact by enabling broader industry adoption of its biomolecular solutions. Tidal Vision develops chitosan-based biomolecular technologies that transform chitosan into high-performance, biodegradable chemistries for water treatment, agriculture, and material science. The company leverages advanced manufacturing technologies and partners with industry leaders to offer its solutions at scale. Tidal Vision positions its products as green chemistries intended to outcompete non-biodegradable alternatives on performance, economics, and convenience. The company is focused on expanding the use of chitosan-based chemistries into new applications globally through industry partnerships. Tidal Vision is headquartered in Bellingham, Washington, has more than 200 employees, and operates facilities in five states. Tidal Vision converts seafood-industry scraps—salmon skin and discarded crab shells—into materials and consumer goods. Its core products include chitosan for textile use and salmon leather sheets sold to fashion designers, plus finished wallets and belts sold in 130 specialty stores. CEO and cofounder Craig Kasberg negotiated with seafood processors to buy scraps and lead the company’s product development. The company has 12 employees and is backed by more than $1 million from investors. Management is pursuing diversification beyond fashion, with coproduction deals for eco-friendly pool clarifiers and a pipeline of products including preservatives, fertilizers, athletic fabrics, car seat cushions and antimicrobial sponges. Tidal Vision aims to supply textile companies and designers while expanding into other markets as sustainable apparel adoption grows.